[CXM] CARDIUM THERAPEUTICS > 2.55 +0.3 ( +13.33%) Open > 2.30 Volume > 73400
Cardium Therapeutics, Inc., a medical technology company, engages in the development, manufacture, and sale of biologic therapeutics and medical devices for cardiovascular and ischemic disease. The company's portfolio of product include Generx, a DNA-based growth factor therapeutic for the treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions; and Corgentin, a pre-clinical DNA-based therapeutic for administration in acute care setting for heart attack patients. It also develops Genvascor, a pre-clinical DNA-based therapeutic designed to induce production of nitric oxide directed at mediating the effects of multiple growth factors to enhance neovascularization and increased blood flow for the treatment of patients with critical limb ischemia. In addition, Cardium Therapeutics develops Excellarate, a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-B; and InnerCool Celsius Control System designed to controllably cool the body in order to reduce cell death and damage following acute ischemic events, such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries, such as adverse neurological outcomes.
 |
